Drug Trial Radar · NCT03875573
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
147
Actual
Start
Nov 6, 2019
Primary completion
Nov 30, 2024
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Jules Bordet InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut Curie; AstraZeneca
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1. the combination of weekly paclitaxel followed by dose-dense doxorubicin-cyclophosphamide (ddAC) and pre-operative radiation therapy (boost dose) on the primary tumour 2. arm 1 with the addition of the anti-PD-L1 antibody durvalumab 3. arm 2 with the addition of the anti-CD73 antibody oleclumab The primary tumour will be excised 2-6 weeks after completion of ddAC. A safety run-in is planned for the 6 first subjects before starting the randomized phase II trial. Those 6 subjects will receive the treatment given in Arm 3.
Conditions
- Luminal B
Interventions
DurvalumabDrug
an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
Stereotactic Body RadiotherapyRadiation
Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
OleclumabDrug
an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Run-in: Evaluation of the immune related or radiation therapy related toxicity of special interestTime frame: 7 months
- Safety Run-in: Evaluation of the feasibility of the primary surgeryTime frame: 7 months
- Phase II: Demonstration of the tumour response in arms 2 or 3 versus arm 1Time frame: 24 months
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitaire Ziekenhuizen
Leuven, Belgium
CHU UCL Namur Sainte-Elisabeth
Namur, Belgium
GZA - Ziekenhuizen (Campus St. Augustinus)
Wilrijk, Belgium
Centre Georges François Leclerc
Dijon, France
Institut Curie
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.